Glycemic control and treatment with isglt2 drugs in type 2 diabetic patients in an urban population attended at a primary care centre

• At: Seville (Spain) (2022)
• Type: Poster
• Poster code: HPS-011
• By: CARRERAS, Sara (Clinical Pharmacy and Pharmaceutical Care Unit. Faculty of Pharmacy and Food Sciences, University of Barcelona, Spain)
• Co-author(s): Ms Sara Carreras, Student (Clinical Pharmacy and Pharmaceutical Care Unit. Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain)
  Mr Josep M Guiu-Segura (Consortium of Health and Social Care of Catalonia, Barcelona, Spain, Barcelona, Spain)
  Mrs Ana Rubio-Dalmau, Consortium of Health and Social Care of Catalonia, Barcelona, Spain (Consortium of Health and Social Care of Catalonia, Barcelona, Spain, Barcelona, Spain)
  Mrs Sonia Moreno (Consortium of Health and Social Care of Catalonia, Barcelona, Spain, Barcelona, Spain)
  Dr Cecilia F. Lastra (Clinical Pharmacy and Pharmaceutical Care Unit. Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain)
  Dr Pilar Modamio (Clinical Pharmacy and Pharmaceutical Care Unit. Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain)
  Dr Eduardo L. Mariño (Clinical Pharmacy and Pharmaceutical Care Unit. Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain)
  
• Abstract:

  Introduction
  Type 2 diabetes mellitus is a chronic disease with a high prevalence. Clinical trials have shown that iSLGT-2 antidiabetic drugs reduce cardiovascular adverse events. However, a low hypoglycaemic effect in the glycaemic control of diabetic patients have been described.
  
  Objectives
  To evaluate changes in iSGLT2 prescription in type 2..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login